沙利度胺联合FOLFOX4方案治疗晚期原发性肝癌的疗效分析

目的 探讨沙利度胺联合FOLFOX4方案治疗晚期原发性肝癌的疗效.方法 选择晚期原发性肝癌患者62例为研究对象,随机分为观察组和对照组,观察组患者接受沙度利胺联合FOLFOX4化疗方案,对照组患者接受FOL-FOX4化疗方案,比较2组患者的近期疗效、不良反应发生率及治疗前后AFP的水平.结果 观察组治疗有效率及疾病控制率均明显高于对照组,差异具有统计学意义(P<0.05).2组患者骨髓抑制、消化道反应、神经毒性、嗜睡、乏力、便秘、皮疹等不良反应的发生率差异无统计学意义(P>0.05).治疗后,2组患者血清的AFP水平均明显降低(P<0.05),且观察组患者AFP的水平明显低于对照组治疗后的水平(P<0.05).结论 沙利度胺联合FOLFOX4化疗方案治疗晚期原发性肝癌可明显提高有效率和疾病控制率,降低患者AFP水平,毒副作用可耐受,值得在临床上推广应用.

Efficacy of Thalidomide Combined with FOLFOX4 for Advanced Hepatocellular Carcinoma

Objective To investigate the efficacy of thalidomide combined with FOLFOX 4 for advanced hepatocellular carcinoma.Methods 62 patients with advanced primary liver cancer were enrolled in the study.62 patients were randomly divid-ed into the observation group and the control group ,the observation group received thalidomide combined with FOLFOX 4 treat-ment and the control group received FOLFOX 4 treatment.The short-term efficacy,incidence of adverse reactions after treatment and the AFP level of the 2 groups were compared.Results Disease control rate of the observation group were significantly higher than those of the control group,there had statistically significant difference (P<0.05).The incidence of bone marrow suppres-sion,gastrointestinal reactions,peripheral neurotoxicity,drowsiness,fatigue,constipation and rash of the 2 groups had no significant difference(P>0.05).The AFP level in the observation group after treatment was significantly lower than before treatment (P<0.05).AFP level in the control group were also significantly lower than before treatment (P<0.05).After treatment,AFP level in the observation group were significantly lower than those of the control group after treatment (P<0.05).Conclusion Thalido-mide combined with FOLFOX 4 can significantly improve treatment efficiency and disease control rate of primary liver cancer ,re-duce AFP level.The side effects can be tolerated ,which is worthy of clinical application.